PERCUTANEOUS-ABSORPTION AND SKIN ERYTHEMA - QUANTIFICATION OF CAPSAICIN AND ITS SYNTHETIC DERIVATIVES FROM GELS INCORPORATED WITH BENZALKONIUM CHLORIDE BY USING NONINVASIVE BIOENGINEERING METHODS
Jy. Fang et al., PERCUTANEOUS-ABSORPTION AND SKIN ERYTHEMA - QUANTIFICATION OF CAPSAICIN AND ITS SYNTHETIC DERIVATIVES FROM GELS INCORPORATED WITH BENZALKONIUM CHLORIDE BY USING NONINVASIVE BIOENGINEERING METHODS, Drug development research, 40(1), 1997, pp. 56-67
Nonivamide (NVA) and sodium nonivamide acetate (SNA) are synthetic der
ivatives of capsaicin. In this study, the cationic surfactant benzalko
nium chloride was incorporated into the Carbopol 940(R) gel bases of c
apsaicin and its synthetic derivatives to evaluate the in vitro percut
aneous absorption capacity. Afterwards, the optimal gel formulation se
lected from the in vitro study was used in a series of in vivo non-inv
asive bioengineering methods. To quantify the skin erythema and irrita
tion caused by capsaicin, NVA, and SNA, laser Doppler flowmetry (LDF),
transepidermal water loss (TEWL), and colorimetry were utilized for d
etermining the cutaneous blood flow and skin barrier impairment to ass
ess the level of irritant reaction. In the in vitro transdermal study,
the gel base with 0.05% benzalkonium chloride possessed the highest p
enetration capacity: this was chosen for the in vivo study. After quan
tification of skin erythema by LDF, capsaicin developed more severe ir
ritation than NVA, and SNA showed no skin irritation or pungent sensat
ion in volunteers. The result of the TEWL experiment suggested that 0.
05% benzalkonium chloride did not cause any skin impairment. Moreover,
the Carbopol 940(R) gel base itself offered a moderate penetration ca
pacity for drugs and avoided any skin irritation. The result of colori
metry confirmed that both Delta a and Delta E* parameters correlated
well with the data of LDF and that they are good indicators of skin er
ythema response. After a series of in vivo applications, SNA was shown
to be a potent analogue of capsaicin with a marked pharmacological ef
fect and moderate percutaneous capacity and reduced skin erythema and
painful sensation. (C) 1997 Wiley-Liss, Inc.